C4XD Names New Chair
This article was originally published in Scrip
C4X Discovery Holdings plc, a drug discovery and design company, has appointed Dr. Clive Dix executive chair. Dix was previously non-executive chair of C4XD's board of directors; now as executive chair he will build upon the strong achievements C4XD has made to date in fulfilling its ambition to become "one of the world's leading hubs for the discovery of novel drugs against critical therapeutic targets." Recent achievements include advances in its Orexin-1, IL-17, GPR142 and NRF-2 programs and the signing of a collaboration with the Structural Genomics Consortium at Oxford University.